3-MeO-PCE first hit the market in 2010 and can be purchased from manufacturers of research chemicals to study this new supplementary compound. This chemical is in the arylcyclohexylamine family and is known to be a hallucinogenic dissociative. The chemical properties of 3-MeO-PCE are very closely related to 3-MeO-PCP.
All chemicals in this family that includes various research compounds have a structure that includes an amine group, and an aromatic ring that has a cyclohexane ring bound to it, however, 3-MeO-PCE also have a substituted methoxy at R3 that is bound to a cyclohexane ring. Other differences include an amino ethyl chain that is in the cyclohexanone ring that is bound to the same carbon as well as an amino ethyl chain that is similar to what is found with MXE. This makes 3-MeO-PCE different that ketamine so most studies show this research chemical as an analog of MXE but also a homolog of 3-MeO-PCP without the supplementary carbons that would complete a piperidine ring.
Via scientific research on 3-MeO-PCE it has been noted to be a NMDA receptor antagonist. This receptor is very important as they let the electrical signals go between the neurons in the brain as well as to the spinal column. When signals pass between the neurons, the NMDA receptors have to be open, chemicals in this family, block the receptors from opening which can cause issues with movement and loss of feeling in the limbs.
The only data available on 3-MeO-PCE is from research studies on the structure and chemical reaction of the chemical. No studies have been conducted to determine the toxicity or harmful effects the chemical may have on animals or humans. Until more research can be conducted, 3-MeO-PCE is not for human consumption. Laboratories that are interested in studying synthetic chemicals in this family can purchase 3-MeO-PCE for further study.